Fluidigm Corporation (NASDAQ: FLDM) engages in the manufacture of proprietary microfluidic systems for the life science and agri-biotech industries. The stock IPO'd in early 2011 at $13.50. Since then it has remained range bound between $12 and $16. There was a brief foray to $20 when it announced a cross-license agreement with Life Technologies Corp (NASDAQ: LIFE) but this warm fuzzy feeling quickly faded, dropping the stock back more »
The recent $5.7 billion hostile takeover bid by Swiss pharmaceutical giant Roche ADR (OTC BB: RHHBY) for U.S. based Illumina (NASDAQ: ILMN) has certainly shined the spotlight on the business of DNA sequencing. Illumina has sought to fend off Roche through the use of a "poison pill" defense.
The takeover is just another indication of the drug company's desire to develop treatments in combination with accompanying diagnostics more »